Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
TOL-463
open-in-new
<h2 id="see-also">See also</h2> <ul><li><a href="/facts/LACTIN-V/SlweD5ep">LACTIN-V</a></li></ul> <h2 id="external-links">External links</h2> <ul><li><a href="https://adisinsight.springer.com/drugs/800047491">TOL-463 - AdisInsight</a></li></ul> <h2 id="references">References</h2> <ol> <li id="fn:1"><p>"TOL 463 - AdisInsight". <a href="https://adisinsight.springer.com/drugs/800047491" target="_blank">https://adisinsight.springer.com/drugs/800047491</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li> <li id="fn:2"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li> <li id="fn:3"><p>Sobel JD, Sobel R (August 2021). "Current and emerging pharmacotherapy for recurrent bacterial vaginosis". Expert Opin Pharmacother. 22 (12): 1593–1600. doi:10.1080/14656566.2021.1904890. PMID 33750246. S2CID 232325625. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li> <li id="fn:4"><p>Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162 – S168. doi:10.1093/cid/ciab1057. PMID 35416967. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></p></li> <li id="fn:5"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></p></li> <li id="fn:6"><p>Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162 – S168. doi:10.1093/cid/ciab1057. PMID 35416967. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></p></li> <li id="fn:7"><p>Sobel JD, Sobel R (August 2021). "Current and emerging pharmacotherapy for recurrent bacterial vaginosis". Expert Opin Pharmacother. 22 (12): 1593–1600. doi:10.1080/14656566.2021.1904890. PMID 33750246. S2CID 232325625. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:7" class="footnote-back-ref">↩</a></p></li> <li id="fn:8"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:8" class="footnote-back-ref">↩</a></p></li> <li id="fn:9"><p>Sobel JD, Sobel R (August 2021). "Current and emerging pharmacotherapy for recurrent bacterial vaginosis". Expert Opin Pharmacother. 22 (12): 1593–1600. doi:10.1080/14656566.2021.1904890. PMID 33750246. S2CID 232325625. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:9" class="footnote-back-ref">↩</a></p></li> <li id="fn:10"><p>Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162 – S168. doi:10.1093/cid/ciab1057. PMID 35416967. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:10" class="footnote-back-ref">↩</a></p></li> <li id="fn:11"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:11" class="footnote-back-ref">↩</a></p></li> <li id="fn:12"><p>Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162 – S168. doi:10.1093/cid/ciab1057. PMID 35416967. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:12" class="footnote-back-ref">↩</a></p></li> <li id="fn:13"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:13" class="footnote-back-ref">↩</a></p></li> <li id="fn:14"><p>Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376090</a> <a href="#fnref:14" class="footnote-back-ref">↩</a></p></li> <li id="fn:15"><p>"TOL 463 - AdisInsight". <a href="https://adisinsight.springer.com/drugs/800047491" target="_blank">https://adisinsight.springer.com/drugs/800047491</a> <a href="#fnref:15" class="footnote-back-ref">↩</a></p></li> <li id="fn:16"><p>"TOL 463 - AdisInsight". <a href="https://adisinsight.springer.com/drugs/800047491" target="_blank">https://adisinsight.springer.com/drugs/800047491</a> <a href="#fnref:16" class="footnote-back-ref">↩</a></p></li> <li id="fn:17"><p>"TOL 463 - AdisInsight". <a href="https://adisinsight.springer.com/drugs/800047491" target="_blank">https://adisinsight.springer.com/drugs/800047491</a> <a href="#fnref:17" class="footnote-back-ref">↩</a></p></li> </ol>